Clinical trials
Phase 2 Choroidal Neovascularization trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 6 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Terminated | 7 |
| Unknown status | 2 |
| Withdrawn | 2 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Allergan | 3 |
| GlaxoSmithKline | 2 |
| Hoffmann-La Roche | 2 |
| Iconic Therapeutics, Inc. | 2 |
| National Eye Institute (NEI) | 2 |
| University Hospital, Bonn | 2 |
| Adverum Biotechnologies, Inc. | 1 |
| Alcon Research | 1 |
| California Retina Consultants | 1 |
| Chengdu Kanghong Biotech Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Choroidal Neovascularization | 37 |
| Macular Degeneration | 27 |
| Angioid Streaks | 3 |
| Diabetic Retinopathy | 2 |
| Macular Edema | 2 |
| Myopia, Degenerative | 2 |
| Pseudoxanthoma Elasticum | 2 |
| Wet Macular Degeneration | 2 |
| Blindness | 1 |
| Eye Diseases | 1 |
Trials
Showing 26 to 37 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.